NCT06271941 Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
| NCT ID | NCT06271941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 892 participants |
| Start Date | 2024-07-19 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 892 participants in total. It began in 2024-07-19 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Large (≥20mm) colorectal polyps often harbor areas of advanced neoplasia, making them immediate colorectal cancer (CRC) precursors. Such polyps have to be completely removed to prevent CRC and to avoid surgery and/or adjuvant therapy. The laterally spreading lesions (LSLs) are removed via endoscopic mucosal resection (EMR). However, recurrence is common. New techniques for LSL resection (hybrid argon plasma coagulation (h-APC) margin and base ablation) have shown a reduction in recurrence following the interventions. We hypothesize that performing hybrid argon plasma coagulation (h-APC) margin and base ablation during EMR of large (≥20mm) colorectal LSLs will lead to lower rates of lesion recurrence compared to Snare tip soft coagulation (STSC) margin ablation.
Eligibility Criteria
Inclusion Criteria: * adult ≥18 years old * patients undergoing EMR for a large (≥20mm) colorectal LSL * patients providing written and informed consent for study participation. Exclusion Criteria: * inflammatory bowel disease; * non-elective colonoscopy; * poor general health (American Society of Anesthesiologists classification \>III); * coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L); * pedunculated polyps (Paris class Ip, Isp); * overt signs of deep submucosal invasive cancer (JNET 3); * biopsy proven invasive carcinoma in a potential study polyp. * Pregnant women
Frequently Asked Questions
Who can join the NCT06271941 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06271941 currently recruiting?
Yes, NCT06271941 is actively recruiting participants. Visit ClinicalTrials.gov or contact Centre hospitalier de l'Université de Montréal (CHUM) to inquire about joining.
Where is the NCT06271941 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT06271941 clinical trial?
NCT06271941 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The trial plans to enroll 892 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.